In a recent study, one dose of modified vaccinia Ankara-Bavarian Nordic vaccine had estimated vaccine effectiveness of 58 percent<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Sept. 17, 2024 (HealthDay News) — One dose of modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine is moderately effective against mpox infection in at-risk communities, according to a study published online Sept. 11 in The BMJ<\/em>.<\/p>\n Christine Navarro, M.D., from Public Health Ontario in Toronto, and colleagues estimated the real-world effectiveness of the MVA-BN vaccine against mpox infection in an emulation of a target trial involving 9,803 men with a history of being tested for syphilis and a laboratory-confirmed bacterial sexually transmitted infection in the previous year or who filled a prescription for HIV pre-exposure prophylaxis in the previous year. Those who had been vaccinated 15 days previously were matched with unvaccinated men in a 1:1 ratio on each day between June 12 and Oct. 27, 2022. A total of 3,204 men who received the vaccine were matched with 3,204 unvaccinated controls.<\/p>\n The researchers identified 71 mpox infections, with 0.09 and 0.20 per 1,000 person-days in the vaccinated and unvaccinated groups, respectively, during the study period of 153 days. For one dose of MVA-BN, the estimated vaccine effectiveness against mpox infection was 58 percent.<\/p>\n “Our findings strengthen the evidence that MVA-BN is effective at preventing mpox infection and should be made available and accessible to communities at risk,” the authors write.<\/p>\n